Boehringer's operating income flat as integration costs weigh
April 17, 2019 at 06:44 AM EDT
German drugmaker Boehringer Ingelheim reported on Wednesday flat operating income of 3.5 billion euros ($4 billion) for 2018, held back by the costs of integrating the animal medicines business it acquired from Sanofi.
